Ian McLeod - Apr 5, 2025 Form 3 Insider Report for Anika Therapeutics, Inc. (ANIK)

Role: VP, CAO and Treasurer
Signature: /s/ Ian McLeod
Stock symbol: ANIK
Transactions as of: Apr 5, 2025
Transactions value $: $0
Form type: 3
Date filed: 4/11/2025, 04:46 PM
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ANIK	Common Stock						16K	Apr 5, 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ANIK	Restricted Stock Unit							Apr 5, 2025	Common Stock	2.2K	$0.00	Direct	F1
holding	ANIK	Stock Option (Right to Buy)							Apr 5, 2025	Common Stock	2.36K	$29.60	Direct	F2, F3
holding	ANIK	Restricted Stock Unit							Apr 5, 2025	Common Stock	5.32K	$0.00	Direct	F4
holding	ANIK	Stock Option (Right to Buy)							Apr 5, 2025	Common Stock	6.35K	$27.98	Direct	F3, F5
holding	ANIK	Restricted Stock Unit							Apr 5, 2025	Common Stock	11.3K	$0.00	Direct	F6
holding	ANIK	Restricted Stock Unit							Apr 5, 2025	Common Stock	2.54K	$0.00	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each RSU represents the contingent right to receive one share of the Company's common stock. 6,590 RSUs were granted on March 9, 2023 and the RSUs vest in three equal annual installments beginning March 9, 2024.
F2	7,086 stock options were granted on March 9, 2023. The stock options vest in three equal annual installments beginning on March 9, 2024.
F3	Represents a 10% premium above the closing price of Anika's common stock on the date of grant.
F4	7,976 RSUs were granted on March 15, 2024. Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025.
F5	9,519 stock options were granted on March 15, 2024. The stock options vest in three equal annual installments beginning on March 15, 2025.
F6	11,324 RSUs were granted on March 14, 2025. Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 14, 2026.
F7	2,536 RSUs were granted on March 14, 2025. Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on the vest date. The 2,536 RSUs represent the Target number of shares that may be earned in conjunction with certain market metrics prescribed under the terms of the performance-based phantom RSU award. The award shall cliff vest on the 3rd anniversary of the grant date, subject to the Compensation Committee's determination of achievement of the award prior to the vest date. The number of shares earned and subject to vest, as determined by the Compensation Committee, may be in a range from Threshold (50% of Target) to Maximum (200% of Target). No shares shall vest for achievement under Threshold.